非小细胞肺癌活检标本ALK表达及临床病理特征分析

Analysis of ALK Expression and Clinicopathological Features in Non-small Cell Lung Cancer Biopsy Specimens

目的分析非小细胞肺癌活检标本人类间变性淋巴瘤激酶(ALK)表达及临床病理特征。方法方便选取接受治疗的非小细胞肺癌患者20例,选取时间为2017年7月—2018年6月,所有患者均接受免疫组织化学(immunohistochemistry,IHC)检测,分析患者的活检标本ALK表达和临床病理特征。结果在20例患者中,经CT和B超引导下穿刺的患者11例(55.00%),支气管镜的患者8例(40.00%),门诊手术切取标本的患者1例(5.00%);在20例非小细胞肺癌患者中,有腺癌患者16例(80.00%),鳞癌患者1例(5.00%),非特指型非小细胞肺癌3例(15.00%);患者年龄小于55岁的患者有8例(40.00%),大于55岁的患者有12例(60.00%);其中吸烟患者有8例(40.00%),不吸烟患者有12例(60.00%);免疫组织化学(IHC)检测的阳性患者2例(10.00%)。结论通过对非小细胞肺癌患者的活检标本ALK进行检测,可以对患者的病情进行协助诊断,并对患者的治疗具有指导作用。

Objective To analyze the expression and clinicopathological features of human anaplastic lymphoma kinase (ALK) in non-small cell lung cancer biopsy specimens. Methods 20 patients with non-small cell lung cancer who underwent treatment were convenient selected and enrolled. The patients were enrolled in the study from July 2017 to June 2018. All patients underwent immunohistochemistry (IHC) analysis. The biopsy specimens of ALK and pathological features were clinically analyzed. Results Of the 20 patients, 11 cases (55.00%) underwent CT and B-guided puncture, 8 cases(40.00%) patients underwent bronchoscopy, and 1 cases(5.00%) patients who underwent surgical surgery. Among the 20 patients with non-small cell lung cancer, 16 patients (80.00%) had adenocarcinoma, 1 patient(5.00%) had squamous cell carcinoma, and 3 patients (15.00%) had non-specific non-small cell lung cancer. The patients were younger than 55 years old. There were 8 patients (40.00%), and 12 patients (60.00%) were older than 55 years old;8 cases(40.00%) were smokers and 12 cases(60.00%) were non-smokers;2 cases(10.00%) cases of immunohistochemistry (IHC) positive patients were detected. Conclusion By detecting the biopsy specimen ALK in patients with non-small cell lung cancer, the patient's condition can be assisted and diagnosed, and the patient's treatment can be guided.